Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual.
about
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individualsDevelopment of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infectionTransplanting supersites of HIV-1 vulnerability.Dynamics of envelope evolution in clade C SHIV-infected pig-tailed macaques during disease progression analyzed by ultra-deep pyrosequencing.The dysfunction of T follicular helper cellsB-cell-lineage immunogen design in vaccine development with HIV-1 as a case studyImproved flow-based method for HIV/SIV envelope-specific memory B-cell evaluation in rhesus macaques.A mechanistic understanding of allosteric immune escape pathways in the HIV-1 envelope glycoprotein.Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypesBinding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding siteHIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trialsAntibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected womenAntibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes.Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccineesComparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design.Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site.Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV.Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes.Neutralizing antibodies and control of HIV: moves and countermoves.Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies.HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages.Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses.HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies.Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.Evolution of Neutralization Response in HIV-1 Subtype C-Infected Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains.Gp120 V5 Is Targeted by the First Wave of Sequential Neutralizing Antibodies in SHIVSF162P3N-Infected Rhesus Macaques.Progress in HIV-1 vaccine developmentBroadly neutralizing antibodies in HIV-1 treatment and prevention
P2860
Q24635002-BCDBF698-7D41-4973-AE4F-FD15C00C9784Q27022652-70D1C73B-3121-42D0-8744-ABD782F300E0Q33854841-97885E5E-81BF-47FA-B180-3A914F90391DQ34200095-557ED017-5E62-4191-BE34-105B0A5EFA8CQ34252448-21F12AB7-5B8E-490C-A96C-FC02195782D5Q34273373-47E4E39B-42B6-4E50-8A97-E7DE3C5D7767Q34345369-CBCFCDFD-FE1D-4A2B-9CA8-2A1429C0AC3AQ34733504-5762DCF4-AF12-430D-9A39-59E20C992EB1Q35034268-72EE5764-54BC-4EC2-B0F8-81634B1D8C7EQ35192937-DDAEC607-F52C-4E8F-8D48-B11655A019E9Q35728947-AF01B12D-986F-43FE-AC47-E3A59164E420Q35943521-907D5283-CC67-4097-928C-132E34F773CDQ36083337-264CAA9F-74FA-428C-B40F-19DE990B8F8BQ36363231-4E47A97F-CF66-4981-AAD1-86BFC1E0FD3FQ36694111-B4518742-2615-4C35-9E0B-1C018BAD3880Q36736392-010CC9BD-F903-461C-ACFA-7C45D3FA78F9Q36753653-39608803-7AA8-46DD-9961-E2A7E4CDAD2BQ36807838-252E8D76-0351-4C83-89CD-4C5DD0587274Q36895518-EC85D27A-FE20-4877-9F49-E15AC7A778D5Q36978671-74DA3B26-C052-4028-B785-C723A7BD371AQ36978861-15B1497A-1F57-4AB5-8E17-25FE9594D3B9Q37409244-7A73D3C2-BCD2-47B4-841A-D14644B36A21Q37625296-FAC16AAC-068D-4DF3-9619-50179200009CQ37730206-7AE809EB-4984-44D4-B687-37BC4E48A7A8Q37971867-A172E9A4-F26E-4452-B9B5-F27CE413C43CQ40290521-D6D72CDC-8EDC-4A40-81EA-00239403FD70Q42270590-18583A27-CA8A-4D47-BE7C-4FF7FA31F926Q46202850-FFB33E10-0EF1-437D-A8EF-20FFF0648170Q52598776-D98EE8FF-E605-4EC1-9B72-865A076ECB0BQ52688325-1AC422DC-75E1-4399-A266-07A9A17E3EADQ55359818-02AE99C8-3CD0-45BC-9E3D-E6C0C5BC8DEBQ55373995-1007BF78-7FED-4F9A-8AFB-590AFCF443B0Q56600657-49087AB9-299D-4113-A5F7-2A62E3397CCDQ57815702-87EFFD49-5479-4A17-B1E6-879D1E416B6D
P2860
Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Isolation of a monoclonal anti ...... subtype C-infected individual.
@ast
Isolation of a monoclonal anti ...... subtype C-infected individual.
@en
type
label
Isolation of a monoclonal anti ...... subtype C-infected individual.
@ast
Isolation of a monoclonal anti ...... subtype C-infected individual.
@en
prefLabel
Isolation of a monoclonal anti ...... subtype C-infected individual.
@ast
Isolation of a monoclonal anti ...... subtype C-infected individual.
@en
P2093
P2860
P50
P356
P1433
P1476
Isolation of a monoclonal anti ...... subtype C-infected individual.
@en
P2093
Andrew Foulger
Bronwen Lambson
Dawn Marshall
Georgia D Tomaras
Hua-Xin Liao
Jae-Sung Yu
John Whitesides
Joshua Amos
M Anthony Moody
P2860
P304
P356
10.1128/JVI.00563-11
P407
P577
2011-05-25T00:00:00Z